Alpha-lipoic acid
Also called: thioctic acid, lipoic acid, lipoate, ALA, R-alpha-lipoic acid, DL-alpha-lipoic acid
Alpha-lipoic acid (thioctic acid) is a compound the body makes and is also found in foods such as red meat, spinach, broccoli, tomatoes, peas, Brussels sprouts and rice bran. Supplements contain the racemic DL form or the R form.
- Category
- Other
- Forms
- DL-alpha-lipoic acid (racemic) or R-alpha-lipoic acid, both synthetic; tablets and capsules (oral). Some trials used intravenous ALA.
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2023 meta-analysis included 10 RCTs (1,242 patients with diabetic sensorimotor polyneuropathy) of oral alpha-lipoic acid alone versus placebo; trials of intravenous ALA or of ALA taken with other supplements were excluded. [4]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BBrain, mood and sleep1 topic
BBlood sugar and weight1 topic
BSeveral areas, whole body or blood1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Symptoms of diabetic polyneuropathy (oral ALA) | B | A 2023 meta-analysis of 10 RCTs (1,242 patients) found better total symptom scores than placebo, with a dose-related trend, but no benefit on vibration perception or nerve conduction results. [4] |
| Nerve conduction in diabetic peripheral neuropathy (intravenous ALA) | B | A 2012 meta-analysis of 15 RCTs of intravenous ALA (300–600 mg/day for 2–4 weeks) found faster nerve conduction than control; the authors note most studies had poor methodological quality. [5] |
| Body weight in adults | B | A 2018 meta-analysis of 12 placebo-controlled trials found slightly lower body weight (−0.69 kg) and BMI (−0.38 kg/m²) with ALA, but no significant change in waist circumference. [6] |
Main constituents: Alpha-lipoic acid (1,2-dithiolane-3-pentanoic acid), an endogenous cofactor found in cells [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Oral trials in diabetic polyneuropathy were analyzed at 600, 1,200 and 1,800 mg/day. [4]
- Intravenous trials used 300–600 mg/day for 2–4 weeks. [5]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score EABCDEA: well known causeE: unlikely cause
LiverTox likelihood score E: unlikely cause of clinically apparent liver injury.
Details and sources - Pregnancy and breastfeedingHealth Canada's monograph requires all products to advise consulting a health care practitioner before use if pregnant, breastfeeding or diabetic.
1 statement in the profile.
Details and sources - Interactions with medicines2 listed
Hypoglycemic (blood-sugar-lowering) agents; Chemotherapy and radiation therapy
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications2 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada NNHPD DL-/R-alpha-lipoic acid monograph (June 27, 2025), adults 18 years and older, oral: DL-alpha-lipoic acid up to 600 mg/day (source …
Details and sources
- MSK states ALA may trigger autoimmune hypoglycemia or insulin autoimmune syndrome (IAS) in genetically predisposed individuals, and that high doses can cause hypoglycemic symptoms. [1]
- Case reports listed by MSK include severe intoxication after high-dose use (one resulting in death), convulsions in a toddler after accidental access, and membranous nephropathy in a woman using ALA for neuropathy. [1]
- Reported adverse effects include nausea, vomiting and dyspepsia. [1]
- Health Canada requires products providing at least 42 mg DL- or 21 mg R-alpha-lipoic acid per day to tell users to stop and consult a professional if sweating, paleness, chills, headache, dizziness or confusion occur, which may be symptoms of serious low blood sugar. [3]
- LiverTox rates ALA likelihood score E (unlikely cause of clinically apparent liver injury); no published reports of liver injury at conventional doses. [2]
- A 2020 meta-analysis of 71 placebo-controlled clinical studies (4,749 subjects) found ALA was not associated with an increased risk of any treatment-emergent adverse event. [7]
Interactions
| With | What happens |
|---|---|
| Drugs that lower blood sugar (hypoglycemic agents) | ALA may produce synergetic effects. [1] |
| Chemotherapy and radiation therapy | MSK states ALA may antagonize their effects because of its antioxidant properties. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Health Canada lists DL-alpha-lipoic acid and R-alpha-lipoic acid (including sodium R-(+)-lipoate) as synthetic source materials; R-form amounts are set at 50% of the DL-form amounts, and the two forms cannot be combined in one product. [3]
- LiverTox states ALA is available in tablets and capsules of 50 to 600 mg. [2]
Regulatory status
- Canada: Health Canada's DL-/R-alpha-lipoic acid monograph (June 27, 2025) covers oral products for adults as a source of antioxidants and to support healthy glucose metabolism. [3]
- US: FDA's published NDI list has 2 entries naming alpha-lipoic acid: a benfotiamine/alpha-lipoic acid combination (NDI 384, 2006-02-07) and magnesium di-R-alpha-lipoate (NDI 745, 2012-02-27). [8]
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [9]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Alpha-lipoic acid (1,2-dithiolane-3-pentanoic acid); supplements contain racemic DL-alpha-lipoic acid or R-alpha-lipoic acid Fatty acids and lipids (dithiolane fatty acid) [P5]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 2 entries naming alpha-lipoic acid or a lipoate (earliest NDI 384 submitted 2006-02-07, a benfotiamine/alpha-lipoic acid combination; most recent NDI 745 submitted 2012-02-27, magnesium di-R-alpha-lipoate). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of alpha-lipoic acid (thioctic acid) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P2]
- The NTP Technical Reports index (TR-001 to TR-606) lists no study of lipoic or thioctic acid (checked 2026-10-29). [P3]
Liver (NIH LiverTox)
- LiverTox likelihood score E: unlikely cause of clinically apparent liver injury. No published reports of serum enzyme elevations or clinically apparent liver injury at conventional doses; in overdose, liver injury may result from shock and ischemia (chapter last updated May 3, 2023). [P6]
Interactions with medicines
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- In 12 healthy volunteers given racemic ALA, absolute bioavailability after a 200 mg oral dose was 29.1 ± 10.3%; half-life was 25.3–32.7 min, and clearance did not differ between 200 and 600 mg (non-saturable kinetics). [P8]
- In 24 healthy adults given 600 mg racemic ALA, both R-(+)- and S-(−)-enantiomers were absorbed rapidly (median tmax 0.33–0.5 h); weight-normalized AUC was 20%–26% (R) and 25%–32% (S) higher in women than men. [P9]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada NNHPD DL-/R-alpha-lipoic acid monograph (June 27, 2025), adults 18 years and older, oral: DL-alpha-lipoic acid up to 600 mg/day (source of antioxidants) or 600 mg/day (healthy glucose metabolism); R-alpha-lipoic acid at 50% of those amounts (300 mg/day). The two forms cannot be combined. [P5]
Pregnancy and breastfeeding
- Health Canada's monograph requires all products to advise consulting a health care practitioner before use if pregnant, breastfeeding or diabetic. [P5]
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- Health Canada NNHPD. Natural health product monograph: DL-alpha-lipoic acid / R-alpha-lipoic acid (date June 27, 2025), 2025-06-27. webprod.hc-sc.gc.ca
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Alpha Lipoic Acid (Last Update: May 3, 2023). NCBI Bookshelf NBK591554, 2023-05-03. ncbi.nlm.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Alpha-Lipoic Acid (Last Updated July 31, 2026), 2026-07-31. mskcc.org
- Teichert J, et al. Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. Int J Clin Pharmacol Ther 1998;36(12):625-628 (PMID 9876998), 1998-12. pubmed.ncbi.nlm.nih.gov
- Hermann R, et al. Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms. Clin Pharmacol 2014;6:195-204 (PMID 25506250), 2014-11-28. pubmed.ncbi.nlm.nih.gov
Sources
- Memorial Sloan Kettering Cancer Center. About Herbs: Alpha-Lipoic Acid (Last Updated July 31, 2026), 2026-07-31. mskcc.org
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Alpha Lipoic Acid (Last Update: May 3, 2023). NCBI Bookshelf NBK591554, 2023-05-03. ncbi.nlm.nih.gov
- Health Canada NNHPD. Natural health product monograph: DL-alpha-lipoic acid / R-alpha-lipoic acid (date June 27, 2025), 2025-06-27. webprod.hc-sc.gc.ca
- Hsieh RY, et al. Effects of oral alpha-lipoic acid treatment on diabetic polyneuropathy: a meta-analysis and systematic review. Nutrients 2023;15(16):3634 (PMID 37630823), 2023-08-18. pubmed.ncbi.nlm.nih.gov
- Han T, et al. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol 2012;167(4):465-471 (PMID 22837391), 2012-10. pubmed.ncbi.nlm.nih.gov
- Namazi N, et al. Alpha-lipoic acid supplement in obesity treatment: a systematic review and meta-analysis of clinical trials. Clin Nutr 2018;37(2):419-428 (PMID 28629898), 2018-04. pubmed.ncbi.nlm.nih.gov
- Fogacci F, et al. Safety evaluation of α-lipoic acid supplementation: a systematic review and meta-analysis of randomized placebo-controlled clinical studies. Antioxidants (Basel) 2020;9(10):1011 (PMID 33086555), 2020-10-19. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · Choline · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.